TD Cowen analyst Tyler Van Buren raised the firm’s price target on Regeneron (REGN) to $960 from $880 and keeps a Buy rating on the shares. The firm updated its model ahead of Q1 results and they slightly decreased Eylea and Libtayo estimates and increased Dupi estimate, bringing non-GAAP EPS estimate for Q1 up to $9.30.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron, Sanofi: FDA approves Dupixent for treatment of CSU in ages 2-11
- Regeneron announces publication of Phase 3 NIMBLE trial results
- Trump names Erica Schwartz CDC Director
- Citizens biotechnology analyst holds analyst/industry conference call
- Telix Pharmaceuticals up 11% to $11.70 after collaboration with Regeneron